newsfilter
← Latest News
GlobeNewswire·

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

  • Ascentage Pharma Group International issued a correction to a previous release stating the 6 months 2026 unaudited interim results webcast time is 7:00 am EDT / 7:00 pm HKT on August 19, 2026, instead of the previously stated 9:00 am EDT / 9:00 pm HKT.
  • The company will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 19, 2026 / 9:00 am HKT on August 20, 2026.
  • The English language investor conference call & webcast is scheduled for 8:00 am EDT / 8:00 pm HKT on August 20, 2026.
  • Ascentage Pharma is conducting registrational Phase III trials for Olverembatinib (POLARIS-2 for CML, POLARIS-1 for Ph+ ALL, POLARIS-3 for SDH-deficient GIST) with FDA & EMA clearance.
  • Registrational Phase III trials for Lisaftoclax include GLORA, GLORA-2, GLORA-3, & GLORA-4 studies targeting various hematologic malignancies such as CLL/SLL, AML, & MDS.
  • The company maintains global partnerships with Takeda, AstraZeneca, Merck, Pfizer, & Innovent, & collaborates with research institutions like Dana-Farber, Mayo Clinic, National Cancer Institute, & University of Michigan.
  • The press release contains forward-looking statements subject to risks & uncertainties detailed in SEC filings, including the 2025 Form 20-F filed on April 29, 2026.